头孢他啶-阿维巴坦成功治疗持续伯克霍尔德菌复合菌血症。
Successful Treatment of Persistent Burkholderia cepacia Complex Bacteremia with Ceftazidime-Avibactam.
机构信息
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA.
出版信息
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.02213-17. Print 2018 Apr.
Abstract
We report our clinical experience treating a 2-month-old infant with congenital diaphragmatic hernia who experienced prolonged bacteremia with complex (Bcc) despite conventional antibiotic therapy and appropriate source control measures. The infection resolved after initiation of ceftazidime-avibactam. Whole-genome sequencing revealed that the isolate most closely resembled and identified the mechanism of resistance that likely contributed to clinical cure with this agent. Ceftazidime-avibactam should be considered salvage therapy for Bcc infections if other treatment options have been exhausted.
摘要
我们报告了一例 2 个月大婴儿的临床经验，该婴儿患有先天性膈疝，尽管采用了常规抗生素治疗和适当的源头控制措施，但仍出现长时间的菌血症，且为复杂（Bcc）感染。在开始使用头孢他啶-阿维巴坦后，感染得到了治愈。全基因组测序显示，该分离株与最相似，并确定了可能导致该药物临床治愈的耐药机制。如果其他治疗方案已用尽，头孢他啶-阿维巴坦应被视为治疗 Bcc 感染的挽救疗法。
相似文献
1
Successful Treatment of Persistent Burkholderia cepacia Complex Bacteremia with Ceftazidime-Avibactam.
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.02213-17. Print 2018 Apr.
2
Successful ceftazidime-avibactam treatment of post-surgery Burkholderia multivorans genomovar II bacteremia and brain abscesses in a young lung transplanted woman with cystic fibrosis.
Transpl Infect Dis. 2019 Jun;21(3):e13082. doi: 10.1111/tid.13082. Epub 2019 Apr 3.
3
Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime-avibactam.
Infection. 2019 Apr;47(2):289-292. doi: 10.1007/s15010-018-1261-y. Epub 2018 Dec 19.
4
"Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Complex and Cystic Fibrosis Isolates.
J Clin Microbiol. 2019 Jul 26;57(8). doi: 10.1128/JCM.00181-19. Print 2019 Aug.
5
Use of ceftazidime/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series.
J Antimicrob Chemother. 2019 May 1;74(5):1425-1429. doi: 10.1093/jac/dky558.
6
Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam.
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00590-18. Print 2018 Sep.
7
Ceftazidime plasma concentration in a patient with cystic fibrosis treated with ceftazidime/avibactam plus trimethoprim/sulfametoxazole for reacutization.
J Chemother. 2019 Nov-Dec;31(7-8):436-438. doi: 10.1080/1120009X.2019.1671654. Epub 2019 Oct 4.
8
Trends in ceftazidime-avibactam activity against multidrug-resistant organisms recovered from respiratory samples of cystic fibrosis patients.
Transpl Infect Dis. 2018 Oct;20(5):e12955. doi: 10.1111/tid.12955. Epub 2018 Jun 25.
9
Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.
ACS Infect Dis. 2017 Jul 14;3(7):502-511. doi: 10.1021/acsinfecdis.7b00020. Epub 2017 Mar 30.
10
Susceptibility of Complex to Ceftazidime/Avibactam and Standard Drugs of Treatment for Cystic Fibrosis Patients.
Microb Drug Resist. 2022 May;28(5):545-550. doi: 10.1089/mdr.2021.0353. Epub 2022 May 5.
引用本文的文献
1
In vitro susceptibility of to ceftazidime-avibactam: A systematic review.
New Microbes New Infect. 2025 May 28;66:101601. doi: 10.1016/j.nmni.2025.101601. eCollection 2025 Aug.
2
Clinical Characteristics of Patients Who Acquired Gram-Negative Bacteria During Ceftazidime-Avibactam Therapy.
Infect Dis Ther. 2025 May;14(5):1027-1042. doi: 10.1007/s40121-025-01126-1. Epub 2025 Apr 2.
3
First case of New Delhi metallo β-lactamase-1 (NDM-1)-producing complex in Iran.
Heliyon. 2024 May 9;10(10):e30895. doi: 10.1016/j.heliyon.2024.e30895. eCollection 2024 May 30.
4
activity of cefiderocol and comparator antibiotics against multidrug-resistant non-fermenting Gram-negative bacilli.
JAC Antimicrob Resist. 2024 Feb 1;6(1):dlae006. doi: 10.1093/jacamr/dlae006. eCollection 2024 Feb.
5
Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review.
Microorganisms. 2023 Jul 13;11(7):1798. doi: 10.3390/microorganisms11071798.
6
New Antimicrobials for the Treatment of Neonatal Sepsis Caused by Multi-Drug-Resistant Bacteria: A Systematic Review.
Antibiotics (Basel). 2023 May 24;12(6):956. doi: 10.3390/antibiotics12060956.
7
Ceftazidime/Avibactam in Ventilator-Associated Pneumonia Due to Difficult-to-Treat Non-Fermenter Gram-Negative Bacteria in COVID-19 Patients: A Case Series and Review of the Literature.
Antibiotics (Basel). 2022 Jul 26;11(8):1007. doi: 10.3390/antibiotics11081007.
8
Ceftazidime-Avibactam as Salvage Therapy in Pediatric Liver Transplantation Patients with Infections Caused by Carbapenem-Resistant .
Infect Drug Resist. 2022 Jun 25;15:3323-3332. doi: 10.2147/IDR.S369368. eCollection 2022.
9
Antibiotic Therapy for Difficult-to-Treat Infections in Lung Transplant Recipients: A Practical Approach.
Antibiotics (Basel). 2022 May 2;11(5):612. doi: 10.3390/antibiotics11050612.
10
Intravenous Ceftazidime-Avibactam in Extremely Premature Neonates With Carbapenem-Resistant Enterobacteriaceae: Two Case Reports.
J Pediatr Pharmacol Ther. 2022;27(2):192-197. doi: 10.5863/1551-6776-27.2.192. Epub 2022 Feb 9.
本文引用的文献
1
A 17-Year Nationwide Study of Burkholderia cepacia Complex Bloodstream Infections Among Patients in the United States Veterans Health Administration.
Clin Infect Dis. 2017 Oct 15;65(8):1253-1259. doi: 10.1093/cid/cix559.
2
Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.
ACS Infect Dis. 2017 Jul 14;3(7):502-511. doi: 10.1021/acsinfecdis.7b00020. Epub 2017 Mar 30.
3
Effect of β-Lactamase inhibitors on in vitro activity of β-Lactam antibiotics against complex species.
Antimicrob Resist Infect Control. 2016 Nov 16;5:44. doi: 10.1186/s13756-016-0142-3. eCollection 2016.
4
Exploring the Role of the Ω-Loop in the Evolution of Ceftazidime Resistance in the PenA β-Lactamase from Burkholderia multivorans, an Important Cystic Fibrosis Pathogen.
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01941-16. Print 2017 Feb.
5
Antibiotic resistance in Burkholderia species.
Drug Resist Updat. 2016 Sep;28:82-90. doi: 10.1016/j.drup.2016.07.003. Epub 2016 Jul 30.
6
Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.
Core Evid. 2014 Jan 24;9:13-25. doi: 10.2147/CE.S40698. eCollection 2014.
7
Kinetics of avibactam inhibition against Class A, C, and D β-lactamases.
J Biol Chem. 2013 Sep 27;288(39):27960-71. doi: 10.1074/jbc.M113.485979. Epub 2013 Aug 2.
8
Insights into β-lactamases from Burkholderia species, two phylogenetically related yet distinct resistance determinants.
J Biol Chem. 2013 Jun 28;288(26):19090-102. doi: 10.1074/jbc.M113.458315. Epub 2013 May 8.
9
Extreme antimicrobial Peptide and polymyxin B resistance in the genus burkholderia.
Front Microbiol. 2011 Jul 22;2:159. doi: 10.3389/fmicb.2011.00159. eCollection 2011.
10
In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.
J Antimicrob Chemother. 2010 Nov;65(11):2376-81. doi: 10.1093/jac/dkq306. Epub 2010 Aug 26.
Zotero 插件